Do you want to read an article? Please log in or register.
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
Hepatitis
Related content
Hepatitis
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort
J Hepatol
Dongelmans E, Hirode G, van Bӧmmel F, Jeng WJ, Chien RN, Chen CH, Kilany M, Su TH, Kao JH, Seto WK, Liang LY, Reikvam DH, Holmberg M, Furquim d'Almeida A, Papatheodoridi M, Maasoumy B, Hansen B, Post R, Pocurull A, Terrault N, Ghany M, Johannessen A, Lok A, Vanwolleghem T, Lens S, Cornberg M, Yuen MF, Wong G, Sonneveld M, Papatheodoridis G, Berg T, Hsu YC, Feld J, Janssen H, RETRACT-B study group
doi: 10.1016/j.jhep.2026.03.030
RECOMMENDED
Hepatitis
Technical systematic review supporting 2025 AASLD Practice Guidelines on management of chronic hepatitis B
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Hepatology
Pan CQ, Saadi S, Ghany MG, Feld JJ, Lim JK, Kim AY, Tang AS, Nguyen MH, Sulkowski MS, Terrault NA, Lok AS, Hegazi M, Hasan B, Fleti F, Nayfeh T, Abusalih MF, Seisa MO, Kabbara Allababidi A, Abbas AS, Prokop LJ, Murad MH, Mohammad KS
doi: 10.1097/HEP.0000000000001584
Hepatitis
Early treatment initiation optimizes virologic and liver outcomes in pediatric patients with chronic hepatitis B aged 0-18 years
Clin Gastroenterol Hepatol
Chen L, Jiang L, Zhao B, Jiang Y, Liu S, Li M, Li Y, Jiang Y, Li M, Wei H, Bao C, Niu J, Zhao J
doi: 10.1016/j.cgh.2026.01.026
Further Publications
A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B
Hepatology
Yanhang G, Xinrui W, Zhongfeng W, Fei K, Lvfeng Y, Weidong L, Jia S, Yunsong Y, Weifeng Z, Jinlin H, Shuangsuo D, Shufen Y, Guoxin H, Bei Z, Hui C, Suling C, Xiaoping D, Xie X, Liu Z, Zhang Z, Song X, Mao Q, Jiang Y, Meng C, Ge F, Su Z, Mao Q, Bai Y, Yu L, Tan Y, Fan H, Jiao Z, Fu X, Hong L, Xu Y, Yan X, Liu J, Gao Y, Gao H, Chen G, Hongguang Q, Cui H, Wu S, Lu X, Liu Z, Liu F, Li X, Sun S, Ding G, Han T, Wang X, Zhao W, Xiang M, Chen X, He W, Lu S, Zeng W, Hu Q, Zhang D, Jin W, Wang D, Wang Y, Zhang C, Wen X, Gao Z, Lv L, Yu K, Li G, Zhang G, Wu G, Niu J
doi: 10.1097/HEP.0000000000001754
Hepatitis
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study
Am J Gastroenterol
Li J, Liu JK, Chau A, Linden S, Tsai PC, Nozaki A, Vutien P, Uojima H, Toyoda H, Honda T, Trinh H, Abe H, Ishikawa T, Atsukawa M, Watanabe T, Tsuji K, Huang DQ, Takaguchi K, Itobayashi E, Marciano S, Rui F, Ni W, Takahashi H, Chuang WL, Dai CY, Huang JF, Huang CF, Yeh ML, Zhu Y, Itokawa N, Kozuka R, Inoue K, Senoh T, Maeda M, Ito T, Morimoto M, Cheung R, Gadano A, Enomoto M, Tanaka Y, Lim SG, Wu C, Yu ML, Nguyen MH
doi: 10.14309/ajg.0000000000003881
Hepatitis
Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B
J Hepatol
Bouquet J, Speer SD, Koenig A, Livingston CM, Savarese M, Lau C, Angelini E, Galwey N, Yates P, Maynard L, You S, Cremer J, Paff M, Theodore D, Elston R, Walker J
doi: 10.1016/j.jhep.2025.12.025
RECOMMENDED
Hepatitis
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Hepatology
Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, Kim AY, Tang AS, Nguyen MH, Naggie S, Sulkowski MS, Rodriguez-Baez N, Chen J, Murad MH, Mohammad KS, Terrault NA
doi: 10.1097/HEP.0000000000001549
HepatitisHepatology
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes
J Gastroenterol Hepatol
Papatheodoridis G, Buti M, Yilmaz Y, Yu ML, El-Kassas M, Alswat K, Fernandez MIC, Eguchi Y, Duseja A, Keklikkiran C, Hamid S, Chan WK, Gordon SC, Roberts SK, George J, Singal AK, Ahmed A, Lam B, Nader F, Henry L, Stepanova M, Alqahtani SA, Younossi ZM
doi: 10.1111/jgh.70533
Hepatitis
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial
J Hepatol
Wedemeyer H, Aleman S, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Lichtman A, Manuilov D, Mercier RC, Arterburn S, Christian-Cox F, Tseng S, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Brunetto MR, Lampertico P
doi: 10.1016/j.jhep.2026.03.046